BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bryan Corporation Announces FDA Approval Of Sterile Talc Powder For The Treatment Of Malignant Pleural Effusion Pleurodesis Via Chest Tube Administration


10/19/2005 5:09:31 PM

WOBURN, Mass., Dec. 16 /PRNewswire/ -- Bryan Corporation, an initiate for chemical pleurodesis solutions, today announced that the U.S. Food and Drug Administration approved its product, Sterile Talc Powder (5 g, 100 ml vial), NDC 63256-200-04, administered intrapleurally via chest tube, as sclerosing agent to decrease the recurrence of malignant pleural effusions in symptomatic patients.

Sterile Talc Powder (Product #1690), is a natural, asbestos- free product, supplied sterile in a single use 100 ml amber glass vial. The recommended dose is 5 g, dissolved in 50-100 ml sodium chloride administered slowly through the chest tube. Each 5 g dosage is sterilized via gamma irradiation and is of a controlled particle size.

This product, which will be available immediately, joins the only other licensed form of talc, Sclerosol Intrapleural Aerosol, also manufactured and marketed by Bryan Corporation. Sclerosol Intrapleural Aerosol is packaged with a chlorofluorocarbon (CFC) propellant for direct insufflation into the pleural cavity intraoperatively or during thoracoscopy.

Both of these talc products are made exclusively by Bryan Corporation, and are covered by an Orphan Drug designation held by Bryan Corporation.

ABOUT BRYAN CORPORATION

Bryan Corporation is a Woburn, MA, based company, devoted, since its founding in 1979, to providing health care professionals with unique, high quality medical devices and innovative pharmaceuticals. For more information on Bryan Corporation, please visit our Web site at http://www.bryancorp.com/.

CONTACT: Bryan Corporation 4 Plympton Street Woburn, MA 01801 Tel. 1-781-935-0004 Toll-free: 1-800-343-7711 info@bryancorp.com

Bryan Corporation

CONTACT: Bryan Corporation, +1-781-935-0004,+1-800-343-7711, info@bryancorp.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES